ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Top Stocks Set to Outperform
Over the Next 1 to 3 Months.
Click for your free picks >>

Quote:

Search for Ticker

Free Membership

Search:

GNVC: Genvec Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

GENVEC INC (NASD)
GNVC	1.02	-0.01	(-0.97%)	Vol. 2,141,872	15:59 ET

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and metastatic melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease.

General Information

GENVEC INC

65 West Watkins Mill Road Gaithersburg, MD 20878 Phone: 240 632-0740 Fax: 240 632-0735 Web: www.genvec.com Email: None

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/11/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	1.03
52 Week High	1.17
52 Week Low	0.30
Beta	2.18
20 Day Moving Average	1,572,281.25
Target Price Consensus	N/A

% Price Change
4 Week	28.75
12 Week	37.33
YTD	139.54

% Price Change Relative to S&P 500
4 Week	23.83
12 Week	23.97
YTD	69.36

Share Information
Shares Outstanding (millions)	106.22
Market Capitalization (millions)	109.41
Short Ratio	3.12
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.03
Current Year EPS Consensus Estimate	-0.17
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/11/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	1.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	50.00%
vs. Previous Quarter	20.00%

Sales Growth
vs. Previous Year	-30.42%
vs. Previous Quarter:	-22.61%

Price Ratios
Price/Book	9.43
Price/Cash Flow	-
Price / Sales	7.91

ROE
09/30/09	-195.66
06/30/09	-193.90
03/31/09	-156.90

ROA
09/30/09	-115.30
06/30/09	-114.51
03/31/09	-97.94

Current Ratio
09/30/09	3.24
06/30/09	2.23
03/31/09	1.89

Quick Ratio
09/30/09	3.24
06/30/09	2.23
03/31/09	1.89

Operating Margin
09/30/09	-148.02
06/30/09	-157.19
03/31/09	-167.80

Net Margin
09/30/09	-147.98
06/30/09	-157.10
03/31/09	-167.77

Pre-Tax Margin
09/30/09	-147.98
06/30/09	-157.10
03/31/09	-167.77

Book Value
09/30/09	0.11
06/30/09	0.10
03/31/09	0.09

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research